Pharmaceutical giant Janssen/Johnson & Johnson (J&J) and generic manufacturer Serum Institute of India (SII) charged the South African government more than the European Union for COVID-19 vaccines – and South Africa assumed all the risk in ‘take-it-or-leave-it’ contracts with Pfizer, J&J and SII. This is according to an analysis of the contracts led by Health […] Continue reading ->
Three years after the launch of its COVID-19 Technology Access Pool (C-TAP) initiative, the World Health Organization (WHO) has secured its first COVID-19 vaccine license from a private pharmaceutical company, the UN health body announced on Tuesday. The agreement with Medigen Vaccine Biologics Corp., a private vaccine manufacturer based in Taiwan, is a welcome but underwhelming […] Continue reading ->
Merely months after securing US Food and Drug Administration (FDA) approval for its Respiratory Syncytial Virus (RSV) vaccine, British pharma giant GSK has taken Pfizer to court for patent violations.  GSK filed the lawsuit in a US federal court in Delaware on Wednesday alleging that Pfizer’s RSV vaccine, Abrysvo, violates four patents surrounding the antigen […] Continue reading ->
With the fate and nature of the pandemic accord currently being negotiated by World Health Organization (WHO) member states still uncertain, global health experts are calling for “realistic” backup plans to protect the world against the next pandemic. “We need an ambitious but implementable pandemic accord – that is the Holy Grail,” Javier Guzman, Director […] Continue reading ->
The licensing agreement reached between Johnson & Johnson (J&J) and the Stop TB Partnership on Thursday to allow the generic production of the tuberculosis drug, bedaquiline, is simply a “stop-gap” measure that applies to a limited number of countries, according to Médecins Sans Frontières (MSF). At least nine countries in the Eastern Europe and Central […] Continue reading ->
The Medicines Patent Pool (MPP) announced sublicensing agreements with seven manufacturers to produce and distribute generic versions of Japanese pharmaceutical company Shinogi’s COVID-19 antiviral treatment in 117 low- and middle-income countries.  Ensitrelvir is an oral antiviral currently only approved in Japan under the country’s emergency regulatory approval system. The drug is being evaluated under a […] Continue reading ->
One of the most intense debates in the pandemic accord negotiations is over how to fast-track the development and equitable rollout of vaccines and medicines, with pharmaceutical companies insisting that any infringement on intellectual property (IP) rights will stifle innovation and that voluntary arrangements are the way forward. A recent event to showcase voluntary licensing […] Continue reading ->
A new “Zero+” version of a proposed World Health Organization pandemic accord being negotiated by member states has dropped previously strong language that conditioned use of public R&D funds to private sector commitments to price transparency and tech transfer of end products, among other measuress. However, the updated draft text, obtained by Health Policy Watch, […] Continue reading ->